Efficacy of Ivosidenib for Patients With Advanced Cholangiocarcinoma With an IDH1 Mutation
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial
JAMA Oncol 2021 Sep 23;[EPub Ahead of Print], AX Zhu, T Macarulla, MM Javle, RK Kelley, SJ Lubner, J Adeva, JM Cleary, DVT Catenacci, MJ Borad, JA Bridgewater, WP Harris, AG Murphy, DY Oh, JR Whisenant, MA Lowery, L Goyal, RT Shroff, AB El-Khoueiry, CX Chamberlain, E Aguado-Fraile, S Choe, B Wu, H Liu, C Gliser, SS Pandya, JW Valle, GK Abou-AlfaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.